In a year where neurology has overtaken cancer as the number one indication prioritized by oligonucleotide drug developers, now is the time to stay at forefront of ASO and siRNA innovation. Returning to Boston, this August, the 5th Oligonucleotides for CNS Summit unites 100+ biopharma leaders across RNA biology, oligonucleotide chemistry, DMPK, pharmacology, and platform technology, to discover the latest advancements in brain delivery, chemistry, nonclinical safety and more!
Join your peers Alnylam Pharmaceuticals, Denali Therapeutics, Genentech, FDA, Novo Nordisk, Regeneron, Servier, Stoke Therapeutics, Ultragenyx Pharmaceutical and more, to overcome key challenges, build cross-modality relations, unpack the latest clinical data and redefine the landscape of oligonucleotide research.
What to Expect:
- Benchmark your chemistry and biology innovations with dual-tracked workshops developed for medicinal chemists and neurobiologists
- Hear from 10+ new speakers, including insights from the FDA and companies breaking ground across neuromuscular, neurodegenerative, neurodevelopmental and ultra-rare indications
- Explore the next wave of delivery tech, from TfR1 and AOCs to computational CNS PK/PD modeling and novel RNA editing approaches
Capitalize on the recent ‘oligonucleotide boom,’ by attending this meeting!
To know more visit: https://ter.li/uw2usc